CAR T-cell therapy programs to improve access for patients with leukemia in Mexico

Alberto Olaya-Vargas, MD, National Institute of Pediatrics, Mexico City, Mexico, discusses the challenge of accessing CAR-T therapies for pediatric leukemias in Mexico. There are plans for a collaborative program in which plasmids will be sourced from Hospital Clínic de Barcelona, followed by manufacturing CAR-T products in Mexico utilizing the CliniMacs platform. However, the absence of a unified regulatory body in Mexico hinders the initiation of these programs. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.